Jazz Pharmaceuticals PLC Call to Discuss Exclusive License Agreement with Pharma Mar SA for Lurbinectedin in the U.S. Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Jazz Pharmaceuticals Investor Update Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Ms. Kathee Littrell, Head of Investor Relations. Ma'am, you may begin.
Thank you, Crystal, and thanks to those of you joining our investor update call today to discuss our exclusive license agreement with PharmaMar for lurbinectedin in the U.S. The press release and the slide presentation accompanying this call are available on the Investors section of our website.
I'd like to remind you that some of the statements we will make on this call relate to future events and performance rather than historical facts and are forward-looking. Examples include statements regarding the potential benefits of the license agreement for lurbinectedin, including the potential accelerated FDA approval and the launch of
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |